Targeted therapies such as trastuzumab (TZ (Herceptin®)) and lapatinib are approved for patients with HER2-positive breast cancer [45,46] but intrinsic and acquired insensitivity presents an important clinical problem [47-50]. Here, ERBB2 is linked to breast carcinoma.